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Abstract
Background: Mycoplasma sp. are well recognized as etiological agents of respiratory and sexually transmitted
disease. Mycoplasma penetrans, a species of Mycoplasma sp., has been frequently detected in HIV-positive patients
and associated with the progression of HIV-associated disease. To date, there is only a single case report describing
M. penetrans as the causative agent of a severe respiratory tract infection in a HIV-negative patient.
Case presentation: In this report, we describe the case of M. penetrans bacteremia in a HIV-negative, 38-year-old,
female, immunocompromised, solid organ transplant patient (combined kidney and pancreas transplantation in 2016),
who was admitted to our hospital with anemic uterine bleeding and fever of 38.3 °C. Several hours before her
admission at our university hospital, a latex bladder catheter was inserted into her uterus and she complained about
fatigue, dizziness and ongoing vaginal bleeding. Laboratory examination showed severe anemia, but microbiological
examination was inconspicuous (culture negative vaginal and cervical smears, negative urine culture). Bacterial blood
cultures showed a growth signal after 4 h, but microscopic examination with Gram staining and subcultures on
different agar media did not identify bacterial pathogens. To identify the bacterial cause of malignancy in the patient,
metagenomic sequencing of the blood culture was performed that identified M. penetrans.
Conclusion: Metagenomic sequencing identified M. penetrans in an immunosuppressed patient with culture-negative
bacteremia. Clinicians should be aware of the opportunistic potential of M. penetrans that may cause severe infections
in certain vulnerable patient populations and the limitations of culture and Gram staining for confirming the presence
of fastidious bacterial pathogens like Mycoplasma spp.
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Background
Mycoplasmataceae are among the smallest self-replicating
organisms known and the only described prokaryotes that
lack a cell wall [1]. They have an extremely reduced gen-
ome size of around 1Mb and lack most genes required for
nutrient metabolism and therefore often adopt a parasitic
lifestyle in their host organisms. Mycoplasmataceae have
been isolated from various body sites in humans; however,
only a few species have been well recognized as etiological
agents of disease [2–8]. Among these the most prevalent
pathogenic Mycoplasma spp. in humans are Mycoplasma
pneumoniae that causes respiratory tract infections and
pneumonia, and the widespread sexually transmitted
Mycoplasma genitalium. Mycoplasma hominis and the
closely related species Ureaplasma urealyticum are com-
mon colonizers of the urogenital tract and have been asso-
ciated with chronic urogenital infections [9, 10].
For the detection of bacterial pathogens in patients with
bacteremia, blood culture is still the most commonly used
diagnostic method in the bacteriology laboratory. How-
ever, culture and Gram staining often remain negative
when fastidious, cell-wall free microorganisms such as
Mycoplasma spp. are the causative agent of infection.
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Therefore, rapid detection of microorganisms is pivotal
for patient management and initiation of adequate anti-
microbial therapy. In cases in which blood culture re-
mains negative but the clinical signs and symptoms of
the patient strongly indicates infectious disease, diagno-
sis can be achieved by using metagenomic sequencing.
Metagenomics allows culture-independent sequencing
of the pathogen’s genome directly from the clinical
specimens and potentially provides insights into the
pathogen’s virulence (by detection of virulence genes)
and drug susceptibility (by identification of resistance
mutations in target genes).
Case presentation
In June 2018, a 38-year-old female patient was admitted
to our hospital with anemic uterine bleeding and fever of
38.3 °C (Fig. 1). Her personal history was remarkable for
diabetes mellitus type I, a combined kidney and pancreas
transplantation in 2016 and known uterine myomas,
which were the origin of several episodes of hemorrhagic
bleeding within the last 2 years. The nulliparous patient
was in regular gynecological examination without surgical
interventions. She was denied implantation of any levo-
norgestrel containing intrauterine device because of
concerns about elevated risk of foreign-body associated
infection in her immunocompromised state (dual im-
munosuppression with tacrolimus and mycophenolate
mofetil; both with stable drug levels).
Upon admission at our university hospital, the patient
complained about fatigue, dizziness and ongoing vaginal
bleeding. Several hours before admission, a latex bladder
catheter was inserted into her uterus, and she received
an intravenous hemostatic treatment with tranexamic
acid and fibrinogen in another hospital. On examination,
the patient was in a reduced general condition but
alert and fully oriented. The temperature was 38.3 °C,
the blood pressure 107/45 mmHg, the pulse 90 beats
per minute, and the respiratory rate and oxygen sat-
uration were in normal range.
Laboratory examination showed severe anemia
(hemoglobin 40 g/L, hematocrit 0.137 L/L, erythro-
cyte count [1.37 × 1012/L]) but normal leucocyte
(4.38 × 109/L) and thrombocyte counts (193 × 109/L).
C-reactive protein was in a normal range (3.3 mg/L).
A microbiological diagnostic workup was undertaken.
The vaginal smear grew normal flora and Staphylococcus
aureus. The cervical smear was PCR-negative for Neis-
seria gonorrhoeae and Chlamydia trachomatis. Two out
of four blood culture bottles turned positive after 5 h
(Bact/Alert® Virtuo, BioMérieux, Marcy-l’Etoile, France).
However, microscopy with Gram stain showed no mi-
croorganisms, and subcultures on different agar media
(i.e. Columbia sheep blood agar, colistin-nalidixic acid
agar, chocolate agar, MacConkey agar, brucella agar,
phenylethyl alcohol agar [all BioMérieux] and a modified
Shepard agar medium [A7; ELITech, Puteaux, France]
remained without growth. In the effort to identify the
cause of the positive growth signal in the blood culture,
5 ml of the blood culture was used for metagenomic se-
quencing on an Illumina MiSeq platform. In detail, 2 ml
erythrocyte lysis buffer (Qiagen, Hilden, Germany) was
added to 5 ml of negative blood culture. It was vortexed
at maximum speed for 15 s and afterwards incubated for
5 min at room temperature, followed by addition of 0.1
volume of 10X Turbo DNAse buffer and 3 μl of Turbo
DNAse (Thermo Fischer Scientific Inc.). The sample was
gently mixed and incubated at 37 °C for 30 min. After-
wards, it was centrifuged at maximum speed for 10 min,
and the supernatant was removed. The pellet was resus-
pended in 650 μl of pre-warmed PM1 buffer from the
AllPrep® PowerFecal® DNA/RNA Kit (Qiagen). DNA ex-
traction from bacterial cells was performed according to
the manufactures’ instructions. Library preparation was
done using the Qiagen® QIAseq FX DNA Library Kit
(Qiagen, Hilden, Germany), according to the producers’
recommendations. Sequencing library quality and size
distribution were analyzed on a Fragment analyzer auto-
mated CE system (Advanced Analytical Technologies
Inc., Heidelberg, Germany), according to the manufac-
turer’s instructions using the Fragment Analyzer 474 HS
NGS Fragment Kit. Sequencing libraries were paired-end
sequenced (2 × 150 bp) on an Illumina MiSeq platform
(Illumina®, San Diego CA, USA).
Raw sequencing reads (FASTQ) were filtered and trimmed
using TRIMMOMATIC [11], applying a threshold PHRED
score of 25. Phylogenetic analysis was done by using the full
length 16S rRNA, rpoB and recA gene sequences of the
followingMycoplasma spp.:M. penetransHF-2 (NCBI acces-
sion number: BA000026.2), M. genitalium G37 (NCBI
accession number: NC_000908.2), M. pneumoniae
M129 (NCBI accession number: NC_000912.1), Myco-
plasma fermentans M64 (NCBI accession number:
NC_014921.1), Mycoplasma salivarium ATCC_23064
(NCBI accession number: NZ_AXZE01000009.1), M.
hominis ATCC_23114 (NCBI accession number: NC_
013511.1), and as outlier U. urealyticum serovar 10
ATCC 33699 (NCBI accession number: NC_011374.1)
was included in the phylogenetic analysis. Phylogenetic
trees were generated with the FastTree MP software [12]
(bootstrap 1000 option, maximum likelihood GTR [gener-
alized time-reversible model] option). The metagenomic
sequence reads covered 99.2% of the published reference
sequence of 1.35862Mb [6]. In the 16S rRNA gene, two
mismatches were found at nucleotide positions C98T and
T221C compared to the reference strain sequence. This
combined genetic information points towards the pres-
ence of M. penetrans in the blood cultures (Fig. 2). In
order to confirm the phylogenetic analysis, metagenomic
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sequences of the negative blood culture from the patient
with a growth signal in the BacT/ALERT system were
classified using Kaiju [13] and yielded 363′851 reads, of
which 78% were annotated as M. penetrans (Add-
itional file 2: Table S1, Additional file 1: Figure S1). An
inoculated blood culture without a growth signal in the
BacT/ALERT system and the non-inoculated blood
culture growth medium were sequenced as negative
controls for the meta-genomic sequencing approach
(Additional file 3: Table S2, Additional file 4: Table S3).
While no M. penetrans reads were identified in both nega-
tive controls, the most frequently detected reads assigned
Fig. 1 Clinical data, microbiological work-up of samples and timeline of diagnostic testing and clinical procedures
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to Enterococcus sp., Streptococcus sp. and Staphylococcus
sp. (Additional file 1: Figure S1).
The patient was taken to the operating theatre for
diagnostic hysteroscopy and endometrial ablation. She
received a preoperative single shot dose of cefazolin
(2 g) intravenously. Since the postoperative course was
without complications, the patient remained afebrile
and the uterine bleeding stopped after the removal of
intrauterine catheter. The M. penetrans bacteremia
was self-limiting, requiring no further antibiotic treat-
ment, and the patient was discharged in stable gen-
eral condition.
Discussion
In this study, we report the case of an immunocom-
promised 38-year-old female patient with culture nega-
tive bacteremia that most likely results from a preceding
urogenital M. penetrans colonization. Previously, only a
few studies have focused on bacteremia caused by uro-
genital Mycoplasma spp. [14, 15]. Colonization rate of
M. penetrans in the urogenital tract of healthy women
and men is unknown; however, M. penetrans seropreva-
lence was < 1% in HIV-negative blood donors [16]. In
congruence, other studies confirmed a low M. penetrans
seroprevalence of 0.3% in the general population [17]. In
contrast, high M. penetrans seroprevalence was found in
HIV-positive patients and increased with progression of
HIV-associated disease [2, 17, 18]. Taken together, these
findings indicate that M. penetrans seroprevalence may
be associated with the immune status of the patient.
However, reports on M. penetrans infection in HIV-
negative individuals are scarce in the literature. To date,
only a single case report exists describing the isolation
of M. penetrans from a HIV-negative patient with a
primary antiphospholipid syndrome, a multisystem
autoimmune condition [19].
As there are substantial difficulties in detecting
fastidious bacterial pathogens like M. penetrans with
culture and Gram staining, we believe that there
might be a significant “under-detection” of M. pene-
trans colonization and infection. Therefore, more
rapid, culture-independent molecular methods are
Fig. 2 Phylogenetic analysis of clinical metagenomic reads detected by metagenomic sequencing of the negative blood culture from the patient
with a growth signal in the BacT/ALERT system (i.e. clinical metagenomic reads). Phylogenetic trees were constructed using the full length 16S
rRNA (a), the rpoB (b) and the recA gene sequences (c) of different Mycoplasma sp. with Ureaplasma urealyticum as outlier
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required to circumvent this potential detection bias.
In recent years, metagenomic sequencing has proven
useful in investigating the pathogenic potential of fas-
tidious microorganisms that can just be laboriously
cultivated directly from clinical specimens [20, 21].
However, use of appropriate controls is pivotal as the
presence of contaminating DNA in blood cultures, ex-
traction chemicals or sequencing reagents may lead to
false interpretation of PCR-based (e.g. 16S rRNA se-
quencing) or meta-genomic sequencing results. One
limitation of meta-genomic sequencing approaches
are the still long turn-around times, and thus, meta-
genomic sequencing results are often not timely avail-
able to the treating physician. This results from the
fact that meta-genomic sequencing is mostly just
employed when the “first-line of diagnostics” (e.g.
Gram stain and culture on solid agar media) has
failed. Also in this case report, meta-genomic sequen-
cing results could just be made available to the phys-
ician after empiric cephalosporin-based therapy had
been administered to the patient and the hysterec-
tomy had been performed. Luckily, the patient cleared
the bacteremia spontaneously most probably due to
bacterial load reduction via hysteroscopy and im-
provement of her general condition, making specific
antibiotic treatment (e.g. with a macrolide antibiotic)
unnecessary. Thus, diagnostic workflows must be im-
proved in order to timely provide meta-genomic se-
quencing results. This requires more rapid library
preparation and sequencing protocols, and most of
all, cheaper sequencing chemicals that enable a cost-
efficient use of meta-genomic sequencing as “first-line
diagnostics” in certain patient populations (e.g. critic-
ally ill patients, transplant recipients, immunocom-
promised patients).
Conclusion
In conclusion, the patient described in our case report is
HIV-negative but immunocompromised (solid organ
transplant). To our knowledge, this is the first report of
M. penetrans bacteremia in an immunocompromised
patient. Although we cannot track back the route of in-
fection in the patient, we assume that the source of the
bacteremia with M. penetrans was due to mucosal trans-
location in the utero-cervical compartment in the con-
text of several gynecological interventions. We could
show that metagenomic sequencing directly from clinical
specimens in patients with culture negative bacteremia
of unknown origin can be a helpful tool to receive an
accurate microbiological diagnosis, thus allowing to po-
tentially switch to a targeted antibiotic treatment and
stop unnecessary empiric treatment for the purposes of
antibiotic stewardship.
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